

# A Study on the Hit to Lead Optimization of Resistin Targeting Antibodies as a Treatment for Non-Alcoholic Fatty Liver Disease

Seoul National University Hospital



METABOLIC	Lead
Product Type	Immunoglobulin Product
Indication	1st indication : Non Alcoholic Fatty Liver Disease (NAFLD) 2nd indication : Triple Negative Breast Cancer (TNBC) 3rd indication : Inflammatory Bowel Disease (IBD)
Target	Resistin
MoA(Mechanism of Action)	<p>Resistin and receptor CAP1 inhibition</p>
Competitiveness	<p>First In Class</p> <p>Resistin antibody attenuates overall metabolic syndrome.</p> <p>Resistin antibody inhibits obesity induced low grade inflammation, which increases the possibility to extend its indication.</p>
Development Stage	Lead
Route of Administration	Prenteral-Intravenous / Subcutaneous Injection